1 Result: Annexon
Disappointing Results in Mirati Therapeutics' SAPPHIRE Study and Annexon's ARCHER Trial Lead to Stock Declines
May 24th, 2023
Mirati Therapeutics, Inc. (Nasdaq: MRTX) revealed disappointing news regarding the SAPPHIRE study, as it failed to meet its primary goal of overall survival in the final analysis. The Phase 3 study aimed to assess the effectiveness of sitravatinib, i. Read more
Load More Content
Want To Find Some News?
Recent Post
-
Top Earnings to Watch: FedEx, TD SYNNEX, and AeroVironment
June 22nd, 2025Herbal Works Inc. Launches Social Media Marketing Campaign
June 18th, 2025
Member Login